Loading...
•
Dec 31, 2025
Design Therapeutics Q4 2025 Earnings Report
Design Therapeutics Q4 2025 Earnings Report
Key Takeaways
Design Therapeutics reported a net loss of $16.0 million for the fourth quarter of 2025 as it continues to advance its GeneTAC clinical portfolio. The company maintains a strong liquidity position with $219.8 million in cash and securities, providing an operating runway into 2029.
Ongoing Phase 1/2 MAD trial for DT-216P2 in Friedreich Ataxia with data update expected in H2 2026.
Phase 2 biomarker trial for DT-168 in FECD is ongoing with data anticipated in H2 2026.
Patient dosing for DT-818 in Myotonic Dystrophy Type-1 is expected to begin in H1 2026.
Cash runway is projected to support planned operations into 2029.
Forward Guidance
Design Therapeutics expects its current cash position to fund operations into 2029 and anticipates several clinical milestones in 2026.
Positive Outlook
- Cash runway expected to fund operations into 2029
- Planned initiation of patient dosing for DT-818 in H1 2026
- Anticipated data update for DT-216P2 in H2 2026
- Anticipated data for DT-168 in H2 2026
- Advancing preclinical characterization for Huntington’s disease program
Challenges Ahead
- Ongoing net losses expected as a clinical-stage company
- Risks associated with biomarker-driven clinical strategies
- Potential for delays in patient enrollment or retention
- Dependence on third-party manufacturers and research organizations
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...